Difficulty: Medium
Average Score: 65%
Practice
The client is taking a glycoprotein IIB/IIIA receptor antagonist for the prevention of stroke. What drug is the client likely taking?
Correct answer
D
Rationale
The correct answer is D) Abciximab. Abciximab is a glycoprotein IIB/IIIA receptor antagonist that is used for the prevention of stroke in certain high-risk patients. This drug works by inhibiting platelet aggregation, reducing the risk of clot formation and subsequent stroke.
A) Plavix (clopidogrel) is a P2Y12 inhibitor, not a glycoprotein IIB/IIIA receptor antagonist. It is commonly used for preventing heart attacks and strokes in patients with cardiovascular diseases.
B) Ticlid (ticlopidine) is another P2Y12 inhibitor, similar to Plavix. It is also used to prevent strokes in patients at risk of clot-related events.
C) Aspirin is an antiplatelet drug that works by inhibiting the formation of thromboxane, another pathway involved in platelet aggregation. While aspirin is commonly used for stroke prevention, it does not specifically target the glycoprotein IIB/IIIA receptor like Abciximab does.
Educational context: Understanding the mechanisms of action of different cardiovascular drugs is crucial for healthcare professionals to make informed decisions when managing patients with cardiovascular conditions. Knowing the specific indications, contraindications, and side effects of each drug class helps in providing optimal care and preventing adverse events. In this case, recognizing the role of glycoprotein IIB/IIIA receptor antagonists in stroke prevention highlights the importance of tailored pharmacological interventions based on individual patient needs and risk factors.
A) Plavix (clopidogrel) is a P2Y12 inhibitor, not a glycoprotein IIB/IIIA receptor antagonist. It is commonly used for preventing heart attacks and strokes in patients with cardiovascular diseases.
B) Ticlid (ticlopidine) is another P2Y12 inhibitor, similar to Plavix. It is also used to prevent strokes in patients at risk of clot-related events.
C) Aspirin is an antiplatelet drug that works by inhibiting the formation of thromboxane, another pathway involved in platelet aggregation. While aspirin is commonly used for stroke prevention, it does not specifically target the glycoprotein IIB/IIIA receptor like Abciximab does.
Educational context: Understanding the mechanisms of action of different cardiovascular drugs is crucial for healthcare professionals to make informed decisions when managing patients with cardiovascular conditions. Knowing the specific indications, contraindications, and side effects of each drug class helps in providing optimal care and preventing adverse events. In this case, recognizing the role of glycoprotein IIB/IIIA receptor antagonists in stroke prevention highlights the importance of tailored pharmacological interventions based on individual patient needs and risk factors.